Mineralys Therapeutics MLYS Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, Mineralys Therapeutics insiders bought $8.76 million of stock on the open market (369K shares) and sold $89.55 million (2.35Mn shares).

• By number of insiders, Mineralys Therapeutics saw one insider buy and 7 insiders sell on the open market over the past 12 months.
• Among Mineralys Therapeutics' insiders, the largest open-market purchases in the past 12 months were by Ra Capital Management, L.P. (Director), totaling $8.76 million (369K shares), most recently on March 30, 2026.
• Meanwhile, the largest open-market sales of MLYS in the past 12 months were by Brian Taylor Slingsby (Director), totaling $46.36 million (1.1Mn shares), most recently on September 22, 2026.
• The latest open-market trade on record is a sale of 75K shares for $1.91 million by Jon Congleton (Chief Executive Officer) on September 30, 2026.
• Outside the open market, Mineralys Therapeutics insiders received 334K shares in stock awards and acquired 686.25K shares through option exercises and conversions over the past 12 months.
• Business Quant data shows Mineralys Therapeutics insiders holding 20.69Mn shares in total in their latest Form 4 filings, or 23.42% of the 88.35Mn shares outstanding; that total is down 0.45% from 20.79Mn shares at the end of Q2 2026 and down 4.56% from 21.68Mn shares at the end of Q3 2025.
• Mineralys Therapeutics insiders hold 800.34K shares directly (3.87% of their total) and 19.89Mn shares (96.13%) indirectly, through entities such as trusts and partnerships.
• MLYS's insider total is spread across 12 insiders who have filed a Form 4 in the past two years.
• MLYS's three largest insider shareholders, per their latest Form 4 filings, are Brian Taylor Slingsby (Director, 7.81Mn shares), Srinivas Akkaraju (Director and 10% owner, 6.27Mn shares) and Ra Capital Management, L.P. (Director, 5.83Mn shares).
• Of the shares held by MLYS insiders, 37.72% belong to Brian Taylor Slingsby.
• A total of 57 Form 4 filings with transactions in Mineralys Therapeutics stock were made over the past 12 months, by 12 insiders.
• These insider figures for Mineralys Therapeutics are based on Form 4 filings through October 2, 2026.